Neuren Pharmaceuticals Posts Sharp Profit Decline
Company Announcements

Neuren Pharmaceuticals Posts Sharp Profit Decline

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals Ltd reported a significant decrease in profit after tax for the first half of 2024, earning A$8.0 million compared to A$47.8 million in the same period last year, a drop of 83%. Despite a substantial increase in royalty revenue from Acadia, the absence of milestone revenue recognized in the previous year heavily impacted the overall earnings. No dividends were paid or declared, and the company anticipates a future milestone revenue of A$77 million related to DAYBUE sales.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Reports Strong Q3 Financial Growth
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Gains from Voucher Sale
TipRanks Australian Auto-Generated NewsdeskNeuren Pharmaceuticals Updates Policy Amid Financial Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App